## Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

| NEUROCRI<br>Form 4<br>May 29, 200  | NE BIOSCIEN  | CES INC  | -  |   |                      |                         |   |  |   |  |
|--|--|--|--|---|----------------------|-------------------------|---|--|---|--|
| FORM 4 UNITED STATES   |  |  |  | SECURITIES AND EXCHANGE COMMISSION<br>Washington D.C. 20549 |                      |                         |   |  | 3235-0287   |  |
| Check th<br>if no long<br>subject to<br>Section 1<br>Form 4 c<br>Form 5<br>obligatio<br>may cont<br>See Instr<br>1(b).                 | ger<br>5<br>16.<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5 | Washington, D.C. 20549<br>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF<br>SECURITIES<br>Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,<br>ection 17(a) of the Public Utility Holding Company Act of 1935 or Section<br>30(h) of the Investment Company Act of 1940 |  |   |                      |                         |   | Expires:<br>Estimated<br>burden hor<br>response. | Estimated average<br>burden hours per<br>response 0.5 |  |
| (Print or Type ]   | Responses)   |  |  |   |                      |                         |   |  |   |  |
|  | Address of Reporting   | g Person <u>*</u>  | Symbol   | OCRINE  | d Ticker or Trad     | -                       | 5. Relationship o<br>Issuer<br>(Che   | f Reporting Per                                  |   |  |
| (Last)<br>CELL GEN<br>FORBES B   | ESYS, INC., 50   | (Middle)<br>O  |  | of Earliest T<br>Day/Year)<br>2008                          | Fransaction          |                         | X Director<br>Officer (give<br>below)   |  | % Owner<br>her (specify                               |  |
| SOUTH SA   | (Street)<br>N<br>CO, CA 94080  |  |  | endment, D<br>onth/Day/Yea                                  | Date Original<br>ar) |                         | 6. Individual or J<br>Applicable Line)<br>_X_ Form filed by<br>Form filed by Person |  | Person  |  |
| (City)   | (State)  | (Zip)  | Та   | ole I - Non-  | Derivative Seci      | urities A               | cquired, Disposed o   | of. or Beneficia                                 | ally Owned  |  |
| 1.Title of<br>Security<br>(Instr. 3)2. Transaction Date<br>(Month/Day/Year)2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) |  |  | 3. 4. Securities 5. 4<br>TransactionAcquired (A) or Sec<br>Code Disposed of (D) Bet<br>(Instr. 8) (Instr. 3, 4 and 5) Ow<br>Fol<br>(A) Tra |   |                      | 5. Amount of Securities | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)                   |  |   |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactio<br>Code<br>(Instr. 8) | 5. Number of<br>orDerivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) | Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                                     |
|---|---|---|---|--|--|-------------------------------------|--------------------|---|-------------------------------------|
|   |   |   |   | Code V                                 | (A) (D)  | Date<br>Exercisable                 | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of Shares |
| Stock<br>Option                                     | \$ 4.76   | 05/28/2008                              |   | А                                      | 15,000   | 06/28/2008                          | 05/28/2015         | Common<br>Stock   | 15,000                              |

## Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

## **Reporting Owners**

| Reporting Owner Name / Address   | Relationships |           |         |       |  |  |
|--|---------------|-----------|---------|-------|--|--|
|  | Director      | 10% Owner | Officer | Other |  |  |
| SHERWIN STEPHEN A<br>CELL GENESYS, INC.<br>500 FORBES BLVD.<br>SOUTH SAN FRANCISCO, CA 94080 | Х             |           |         |       |  |  |
| Signatures   |               |           |         |       |  |  |
| Margaret E. Valeur-Jensen, By Power of Attorney  | 05/29/2008    |           |         |       |  |  |
| <u>**</u> Signature of Reporting Person  |               | Date      | e       |       |  |  |

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents option of which 1/12th of the shares underlying the option becomes vested and exercisable on June 28, 2008, an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.